Tag Archive for: GMP

Link Biologics completes IND-enabling preclinical programme for LB001, a first-in-class novel therapy for dry eye disease

Completion of key IND-enabling activities represents a major development milestone for LB001 IND submission remains on track for Q1 2027, followed by initiation of a Phase 1/2 clinical study Manufacturing scale-up completed, providing supply for planned clinical studies London, UK – 5 November 2026 – Link Biologics (“Link” or “the Company”), the biotech developing first-in-class […]

© Optimum Strategic Communications.